SCHEMBL1482889

SCHEMBL1482889

Cn1cc(-c2ccc(C34C=CCN(CC3)C4)cn2)cn1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CHEK1 O14757 1/20 0.36
FYN P06241 5/20 0.35
PIM1 P11309 3/20 0.34
MAPT P10636 1/20 0.34
USP30 Q70CQ3 1/20 0.33
KDM1A O60341 1/20 0.33
MAPK1 P28482 1/20 0.33
KDR P35968 2/20 0.32
TGFBR1 P36897 1/20 0.32
MAPK14 Q16539 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
FGFR3 P22607 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4267971 0.99 ALOX5AP (0.38) ALOX5APCYP11B1CYP11B2CHEK1FYN
SCHEMBL4475112 0.83 CHRNA7 (0.37) ALOX5APPIM1KDM1AMAPK14
SCHEMBL4463819 0.83 HSD11B1 (0.38) CYP11B1CYP11B2
SCHEMBL4461401 0.82 ALOX5AP (0.31) ALOX5APKDM1A
SCHEMBL4463770 0.82 ALOX5AP (0.34) ALOX5APCYP11B1CYP11B2CHEK1GSK3B
Bromide SCHEMBL4466117 0.82 HSD11B1 (0.37) CYP11B1CYP11B2
SCHEMBL2678254 0.81 ALOX5AP (0.43) ALOX5APCYP11B1CYP11B2CHEK1FYN
SCHEMBL4470449 0.81 SLC6A2 (0.38) FYNKDM1A
SCHEMBL4463735 0.81 RXFP1 (0.39) CYP11B1FYN
Hydrochloric Acid SCHEMBL2678766 0.80 ALOX5AP (0.42) ALOX5APCYP11B1CYP11B2CHEK1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541440-B2 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics SANOFI (FR) 2013-09-24 US claimed
US-20110077264-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2011-03-31 US claimed
US-7863290-B2 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2011-01-04 US claimed
EP-1915375-B1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-07 EP claimed
US-20080146608-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2008-06-19 US claimed
US-8541440-B2 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics SANOFI (FR) 2013-09-24 US disclosed
US-20110077264-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2011-03-31 US disclosed
US-7863290-B2 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
EP-1915375-B1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-07 EP disclosed
US-20080146608-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2008-06-19 US disclosed
EP-1915375-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2008-04-30 EP disclosed
WO-2007020344-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077264-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS TPMT, DPYD, IMPDH1 ALOX5AP 195/4885CYP11B1 205/4885CYP11B2 248/4885
US-20080146608-A1 DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS TPMT, DPYD, IMPDH1 ALOX5AP 195/4885CYP11B1 205/4885CYP11B2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.